echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nat Commun: Scientists discover potential therapeutic target for Alzheimer's disease!

    Nat Commun: Scientists discover potential therapeutic target for Alzheimer's disease!

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alzheimer's disease occurs in familial and sporadic forms


    immune immune stem cells

    Recently, researchers from the University of Sherbrooke published a research paper titled "Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer's disease mouse model" on Nat Commun, studying stearoyl-CoA The role of desaturase (SCD), a key regulator of fatty acid desaturation, in AD pathogenesis


    A 3xTg mouse model of AD14 carrying human APPSwe, tauP301L and PS1M146V mutations develops symptoms of learning and memory impairment as early as 6 months of age, before the onset of overt amyloid plaques and neurofibrillary tangles


    Given that fatty acid metabolism genes, including SCD, are markedly dysregulated in the hippocampus during symptomatic stages, the researchers hypothesized that SCD activity may contribute to the observed transcriptomic disturbances


    Figure SCDi infusion potently modulates gene expression in the hippocampus of 3xTg with major effects on immune and synapse-related genes

    Figure SCDi infusion potently modulates gene expression in the hippocampus of 3xTg with major effects on immune and synapse-related genes

    In conclusion, this study demonstrates that brain fatty acid metabolism links AD genes with downstream immune, synaptic, and dysfunctional disorders, identifying SCD as a potential target for AD therapy


    references:

    references:

    Hamilton, LK, Moquin-Beaudry, G.


    Hamilton, LK, Moquin-Beaudry, G.
    , Mangahas, CL et al.
    Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer's disease mouse model.
    Nat Commun 13, 2061 (2022).
    https://doi .
    org/10.
    1038/s41467-022-29506-y
    https://doi.
    org/10.
    1038/s41467-022-29506-y


    Comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.